Lonza confirms interest in capsule maker

Following press speculation, Swiss pharmaceutical and biotech ingredient supplier Lonza (VTX: LONN) has confirmed that it is in final negotiations to acquire a leading drug capsule maker.

Lonza says that in talks with private equity firm KKR, it has expressed a strong interest in acquiring its subsidiary Capsugel, as it would fit perfectly with Lonza’s Healthcare Continuum strategy and strengthen its position as leading supplier to a number of important healthcare markets. A successful acquisition would be value adding and be within Lonza’s stated acquisition criteria.

Lonza emphasizes that there can be no certainty as to the outcome of the discussions or whether an acquisition will be completed. More detailed information will follow in case of any significant developments.